Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging
Publication year
2014Source
The Journal of Nuclear Medicine (1978), 55, 5, (2014), pp. 701-704ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Medical Imaging
Nuclear Medicine
Journal title
The Journal of Nuclear Medicine (1978)
Volume
vol. 55
Issue
iss. 5
Page start
p. 701
Page end
p. 704
Subject
Radboudumc 9: Rare cancers RIMLS: Radboud Institute for Molecular Life SciencesAbstract
Folate receptor (FR) can be used as a therapeutic target because of its expression on different epithelial cancers, such as ovarian, non-small cell lung, endometrial, and breast cancer. Assessing FR expression in tumors may help to identify patients who can benefit from FR-targeted therapeutics, such as vintafolide and farletuzumab. Different methods exist to detect FR expression. Tissue sampling has limited clinical utility, mainly because it requires an invasive procedure. (99m)Tc-etarfolatide, a (99m)Tc-labeled folate conjugate, is in late-phase trials in Europe and the United States. It allows noninvasive, whole-body imaging of the FR. This review focuses on this FR-imaging agent and how it may be used to direct FR-targeted therapy.
This item appears in the following Collection(s)
- Academic publications [227436]
- Faculty of Medical Sciences [86157]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.